<unk>  is an antineoplastic that is FDA approved for the treatment of single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include alopecia, injection site reaction, diarrhea, nausea,<unk> omiting, asthenia, neuromyopathy.
Vinorelbine
Taxane
Zorubicin
Paclitaxel
Doxorubicin hydrochloride
Idoxuridine
Estramustine
Floxuridine